A major legal battle is taking shape in 2026 over one of the most widely implanted orthopedic devices in recent years. The Zimmer Biomet CPT Hip lawsuit wave has accelerated rapidly, with individual cases filed in courts across all 50 states following a July 2024 recall and a September 2024 FDA safety warning. This week, the Judicial Panel on Multidistrict Litigation held its July 30, 2026 Asheville hearing session — a critical event that signals the litigation landscape for the CPT Hip System is about to fundamentally change. If you or someone you love received a Zimmer Biomet CPT Hip System implant and experienced a fracture, revision surgery, or chronic pain, understanding where this litigation stands right now could be the most important step you take.
What Is the Zimmer Biomet CPT Hip System and Why Was It Recalled?
The Zimmer Biomet CPT Hip System Femoral Stem with a 12/14 Neck Taper is a cobalt-chromium alloy hip replacement device that was widely implanted in patients undergoing total hip arthroplasty. Hip replacement is the single most common elective surgery performed in the United States, with more than 450,000 procedures performed annually, according to the CDC. Given those numbers, even a small percentage of defective implants translates into tens of thousands of patients at risk.
On July 2, 2024, Zimmer Biomet issued a voluntary recall of the CPT Hip System Femoral Stem 12/14 Neck Taper, citing an elevated risk of postoperative periprosthetic femoral fracture (PFF). The recall was logged in the FDA’s enforcement database and covered devices that had already been implanted in patients across the country. Critically, while Zimmer Biomet phased out sales of the device by December 2024, the implanted devices remain inside tens of thousands of patients whose bodies continue to carry the same fracture risk that prompted the recall in the first place.
Following the recall, in September 2024 the FDA went a step further, recommending that surgeons use an alternative device to Zimmer Biomet’s CPT Hip System wherever clinically feasible. Zimmer Biomet also issued a Dear Surgeon letter echoing this guidance and acknowledging the fracture risk — a fact that plaintiffs’ attorneys are now citing as evidence that Zimmer Biomet had internal knowledge of the danger before patients were adequately warned. By contrast, Zimmer’s own Charnley–Marcel–Kerboull (CMK) stem system carries a significantly lower chance of breaking or causing patients to fracture their thigh bones, underscoring that safer alternatives were available all along.
The Science Behind the Fracture Risk: What Studies Show
The central scientific claim in every Zimmer Biomet CPT Hip lawsuit filed in 2026 is rooted in a troubling materials comparison. The CPT Hip System is constructed from a cobalt-chromium alloy, and studies cited by both the FDA and the UK Medicines and Healthcare products Regulatory Agency (MHRA) found that patients implanted with this device face a 1.4% periprosthetic femoral fracture rate — almost double the fracture rate of comparable artificial hips. For context, comparable hip systems made from stainless steel carry a fracture rate of only 0.6% to 1.0%. That means patients with the CPT device face roughly twice the fracture risk of patients who received functionally similar devices made from a different material.
The disparity is made starker when you consider Zimmer’s own CMK stem system, which has a much lower chance of breaking or causing patients to fracture their thigh bones. The existence of a safer alternative within Zimmer’s own product portfolio is a detail plaintiffs’ lawyers are expected to emphasize heavily at trial.
The UK MHRA’s Device Safety Information notice (DSI/2024/007) specifically identified the cobalt-chromium alloy composition as the material driver of this elevated risk. The FDA’s September 17, 2024 Medical Device Safety Communication reinforced this finding and warned healthcare providers to consider alternatives where available. This dual-regulator confirmation — from both U.S. and UK authorities — gives plaintiffs a powerful foundation for establishing that the device was unreasonably dangerous and that Zimmer Biomet knew or should have known about the risk.
| Data Point | CPT Hip System (Cobalt-Chromium) | Comparable Hip Systems (Stainless Steel) |
|---|---|---|
| Periprosthetic Femoral Fracture Rate | 1.4% | 0.6%–1.0% |
| Relative Fracture Risk | Nearly double comparable devices | Baseline reference |
| Regulatory Action | FDA Safety Communication (Sept. 2024); MHRA DSI/2024/007 | No equivalent warnings issued |
| Recall Status | Voluntary recall issued July 2, 2024 | No recall |
| Sales Status as of 2026 | Phased out by December 2024 | Actively marketed |
Injuries Linked to the CPT Hip System: What Patients Experienced
The injuries reported in connection with the Zimmer Biomet CPT Hip System follow a recognizable pattern that orthopedic specialists have come to associate specifically with periprosthetic femoral fracture events. Many patients describe a period of worsening thigh pain and instability in the months or years following their initial hip replacement — symptoms that are often misattributed to normal post-surgical recovery. Then, frequently without any significant trauma or fall, the femur fractures around or near the implant.
The consequences of a periprosthetic femoral fracture are severe. Patients typically require emergency revision surgery — a procedure that is significantly more complex, more dangerous, and more expensive than the original hip replacement. Recovery from revision surgery is prolonged, and many patients never fully regain the mobility they had before the fracture occurred. For elderly patients, the complications can be life-threatening. Common injuries and outcomes reported in 2026 CPT Hip lawsuits include:
- Periprosthetic femoral fracture (fracture of the thigh bone around the implant)
- Emergency revision hip surgery
- Permanent loss of mobility or function
- Chronic thigh pain and nerve damage
- Prolonged hospitalization and rehabilitation
- Infection following revision surgery
- Wrongful death in cases involving elderly or medically vulnerable patients
The sudden, traumatic nature of these fractures — and the fact that patients received no adequate warning that their implant carried nearly double the fracture risk of comparable devices — forms the emotional and legal core of most CPT Hip System claims filed in 2026.
Who Qualifies to File a Zimmer Biomet CPT Hip Lawsuit in 2026?
Attorneys actively accepting Zimmer Biomet CPT Hip cases in 2026 are generally focusing on patients who meet a combination of medical, device, and timing criteria. While every case is evaluated individually, the qualifying profile that has emerged looks like this:
- Device confirmation: You received a Zimmer Biomet CPT Hip System Femoral Stem with a 12/14 Neck Taper, typically identified through surgical records or implant card documentation.
- Qualifying injury: You suffered a periprosthetic femoral fracture, required revision surgery, or experienced significant complications attributable to the implant.
- Timeline: Your injury occurred after the implantation of the CPT Hip System and before the statute of limitations for your state has expired.
- Causation link: Medical records support a connection between the CPT implant and the injury you experienced.
It is also worth noting that as of October 2026, lawyers are actively accepting Zimmer lawsuits involving models of the company’s M/L Taper Hip Prosthesis used with Zimmer’s Versys Femoral Head — a related but distinct product line that has drawn similar scrutiny. If you received either the CPT Hip System or the M/L Taper Hip Prosthesis with a Versys Femoral Head and experienced complications, you may have grounds for a claim.
Family members of patients who died as a result of complications linked to the CPT Hip System may also be eligible to pursue wrongful death claims on behalf of their loved ones. Consulting with a mass tort attorney who handles Zimmer Biomet cases is the most reliable way to determine whether your specific situation qualifies.
The Pre-MDL Filing Window: Why July 2026 Is a Pivotal Moment
The July 30, 2026 Judicial Panel on Multidistrict Litigation hearing in Asheville is not a routine procedural step — it is a turning point that will shape every Zimmer Biomet CPT Hip case filed in 2026 and beyond. When the JPML consolidates cases into a multidistrict litigation, individual plaintiffs gain access to shared discovery, coordinated expert witnesses, and bellwether trials that generate settlement leverage across the entire docket. For defendants like Zimmer Biomet, an MDL also creates pressure to resolve cases at scale rather than litigating each one individually.
The period immediately before MDL consolidation is historically one of the most strategically important windows for new plaintiffs. Cases filed early tend to be positioned at the front of the litigation queue, may receive earlier discovery benefits, and can be influential in shaping the bellwether trial pool that ultimately drives global settlement negotiations. Once an MDL is formally established and the docket grows, newer filers are typically placed further back in line.
The momentum in this litigation is significant. Cases have been filed across all 50 states, and the July 2026 JPML hearing signals that consolidation is likely imminent. For patients who have been monitoring this situation but have not yet filed, the window to act with maximum strategic advantage is narrowing. Statutes of limitations vary by state and typically run from the date of injury or the date a patient knew or should have known their injury was linked to the device — meaning delay carries real legal risk.
Frequently Asked Questions About the Zimmer Biomet CPT Hip Lawsuit
What is the Zimmer Biomet CPT Hip System recall about?
On July 2, 2024, Zimmer Biomet voluntarily recalled the CPT Hip System Femoral Stem with a 12/14 Neck Taper due to an elevated risk of periprosthetic femoral fracture — a fracture of the thigh bone around the implant. The device’s cobalt-chromium alloy construction was identified as the primary driver of a 1.4% fracture rate, nearly double the rate seen in comparable stainless steel devices. The FDA followed in September 2024 with a Medical Device Safety Communication recommending that surgeons use alternative devices where possible. Zimmer Biomet phased out sales of the CPT Hip System by December 2024, but implanted devices remain inside patients across the country.
Can I still file a Zimmer Biomet CPT Hip lawsuit in 2026?
Yes. As of mid-2026, attorneys are actively accepting new CPT Hip System cases, and the litigation is still in its early consolidation phase. The July 30, 2026 JPML hearing in Asheville may result in MDL formation, which would centralize cases for coordinated pretrial proceedings. Filing before or shortly after MDL consolidation generally provides strategic advantages. However, statutes of limitations vary by state, and waiting too long can permanently bar a claim. If you believe you have a qualifying injury, consulting an attorney as soon as possible is strongly advisable.
Has an MDL been formed for the Zimmer Biomet CPT Hip System?
As of the date of this article, a formal MDL has not yet been established, but the July 30, 2026 JPML hearing in Asheville is a strong indicator that consolidation is being actively considered. Cases have been filed across all 50 states, and the volume and geographic spread of litigation is consistent with the profile of cases that the JPML typically consolidates. An MDL ruling could come within weeks of the hearing, and attorneys are encouraging eligible patients to file now to avoid being disadvantaged by later placement in the docket.
What injuries qualify for a CPT Hip System lawsuit?
The primary qualifying injury in CPT Hip System litigation is periprosthetic femoral fracture — a fracture of the thigh bone at or near the site of the implant. Patients who required revision surgery as a result of this fracture, or who experienced related complications such as chronic pain, permanent mobility loss, nerve damage, or infection following revision, may also qualify. Wrongful death claims may be available for the families of patients who died as a result of complications. Device confirmation through surgical or medical records is an important threshold requirement for most attorneys evaluating cases.
How much could a Zimmer Biomet CPT Hip lawsuit be worth?
It is too early in the litigation to predict settlement values with confidence, as no bellwether trials have been completed and no global settlement has been announced. In comparable hip implant mass tort litigations, individual case values have ranged from tens of thousands to several hundred thousand dollars, depending on the severity of the injury, the extent of medical treatment required, lost wages, and the long-term impact on quality of life. Cases involving revision surgery, permanent disability, or wrongful death have historically commanded higher valuations. An experienced mass tort attorney can provide a more individualized assessment based on your specific medical records and circumstances.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.